Lucid Diagnostics Inc. (LUCD)
Detects precancerous changes in the esophagus using a simple cell collection device.
$0.91+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-8.6%
The outlook
LUCD is trading near its 52-week low, well below both its 50- and 200-day moving averages, reflecting weak recent momentum. Analyst coverage leans bearish overall, though the average price target sits significantly above the current price at roughly +332%. The stock remains highly speculative with minimal upside in its recent trend.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +332% vs current price
Analyst price target
~12-month · 5 analysts$3.95average target+332.0% vs now
Now $0.91
Low $2.00High $9.25
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$174.4M
52-wk high
$1.63
52-wk low
$0.90
50-day avg
$1.01
200-day avg
$1.14
Trailing P/E
—